Trial · NCT06512207
A Study on the Efficacy of Androgen Deprivation Therapy Combined With Anti-PD-1 Therapy in Advanced Lung Cancer
NCT06512207, Not applicable, Recruiting, Jinzhou Medical University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Study on the Efficacy of Androgen Deprivation Therapy Combined With Anti-PD-1 Therapy in Advanced Lung Cancer. Trials, record NCT06512207. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06512207
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study on the Efficacy of Androgen Deprivation Therapy Combined With Anti-PD-1 Therapy in Advanced Lung Cancer
- NCT number
- NCT06512207
- Status
- Recruiting
- Phases
- Not applicable
- Enrollment
- 80 participants, estimated
- Lead sponsor
- Jinzhou Medical University
- Conditions
- NSCLC, Stage III, NSCLC, Stage IV
- Interventions
- Leuprorelin acetate + Sintilimab, Sintilimab
- First posted
- 2024-07-22
- Last updated
- 2025-09-09
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Participants with Complete Response (CR) | Efficacy evaluations are scheduled at 6 weeks,12 weeks and 18 weeks post treatment | Disappearance of all target lesions, with nodular diseases excluded and target nodules reduced to \<10mm in short axis. |
| Primary | Number of Participants with Partial Response (PR) | Efficacy evaluations are scheduled at 6 weeks,12 weeks and 18 weeks post treatment | Reduction of at least 30% in the sum of diameters of all measurable target lesions compared to baseline |
| Primary | Number of Participants with Disease Progression (PD) | Efficacy evaluations are scheduled at 6 weeks,12 weeks and 18 weeks post treatment | A 20% increase in the sum of the diameters of all measurable target lesions over the entire study period (using the smallest baseline value if it is the smallest), coupled with an absolute increase in the sum of diameters of at least 5mm. The appearance of one or more new lesions is also considered disease progression. |
| Primary | Number of Participants with Stable Disease (SD) | Efficacy evaluations are scheduled at 6 weeks,12 weeks and 18 weeks post treatment | Lesion reduction not meeting PR criteria nor sufficient increase for PD, falling in between these two endpoints. The minimum sum of diameters during the study period can be used as a reference. |
| Primary | Quantity of Peripheral Blood Lymphocytes | Laboratory evaluations are scheduled before treatment, at 3 weeks post-treatment, and at 6 weeks post-treatment | Assessment of peripheral blood lymphocyte quantity, comparing patients before and after a treatment cycle |
| Primary | Composition of Peripheral Blood Lymphocytes | Laboratory evaluations are scheduled before treatment, at 3 weeks post-treatment, and at 6 weeks post-treatment. | Assessment of peripheral blood lymphocyte composition, comparing patients before and after a treatment cycle |
| Primary | Status of Recent Thymic Emigrants (RTEs) | Evaluations are scheduled before treatment, at 3 weeks post-treatment, and at 6 weeks post-treatment. | Assessment of the status of Recent Thymic Emigrants (RTEs), comparing patients before and after a treatment cycle |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06512207
GET https://conductscience.org/api/trials/v1/NCT06512207/registered